AbbVie Inc. is 215.9x more valuable than Zymeworks Inc. by market capitalization ($399.47 B vs $1.85 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ZYME | ABBV |
|---|---|---|
| Market cap | $1.85 B | $399.47 B |
| US-listed rank | #2155 | #28 |
| Revenue (latest FY) | $105.97M | $61.16B |
| Net income (latest FY) | -$81.13M | $4.23B |
| Net margin | -76.6% | 6.9% |
| P/E (trailing FY) | - | 94.5 |
| SEC filings | 324 | 1,008 |
AbbVie Inc. is 215.9x more valuable than Zymeworks Inc. by market capitalization ($399.47 B vs $1.85 B).
In their latest fiscal years, Zymeworks Inc. reported $105.97M in revenue while AbbVie Inc. reported $61.16B.
Full pages: Zymeworks Inc. and AbbVie Inc., or browse the full rankings.